The membrane-proximal external region of HIV-1 gp41: A vaccine target worth exploring

AIDS

Volumn 19, Issue 16, 2005, Pages 1725-1737

  Zwick, Michael B ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Fusion inhibitors; HIV gp41; Membrane proximal region; Neutralizing antibodies; Vaccine design

Indexed keywords

ANTIRETROVIRUS AGENT; COAT PROTEIN; ENFUVIRTIDE; GLYCOPROTEIN 41; GLYCOPROTEIN GP 120; HEPATITIS B SURFACE ANTIGEN; HLA DR ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G 1B12; INFLUENZA VIRUS HEMAGGLUTININ; MALTOSE BINDING PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 4E10; MONOCLONAL ANTIBODY B12; MONOCLONAL ANTIBODY Z13; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG TARGETING; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; NONHUMAN; POTYVIRUS; PRIORITY JOURNAL; VIRUS PARTICLE;

EID: 27544481277     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000189850.83322.41     Document Type: Editorial

References (149)

1. Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 2001; 20:63-75.
2. Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol 2002; 2:706-713.
3. Zinkernagel RM, LaMarre A, Ciurea A, Hunziker L, Ochsenbein AF, McCoy KD, et al. Neutralizing antiviral antibody responses. Adv Immunol 2001; 79:1-53.
4. Ferrantelli F, Ruprecht RM. Neutralizing antibodies against HIV - back in the major leagues? Curr Opin Immunol 2002; 14:495-502.
5. Mascola JR. Defining the protective antibody response for HIV-1. Curr Mol Med 2003; 3:209-216.
6. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5:233-236.
7. Klausner RD, Fauci AS, Corey L, Nabel GJ, Gayle H, Berkley S, et al. Medicine. The need for a global HIV vaccine enterprise. Science 2003; 300:2036-2039.
8. Kostrikis LG, Cao Y, Ngai H, Moore JP, Ho DD. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol 1996; 70:445-458.
9. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003; 100:4144-4149.
10. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307-312.
11. Mascola JR. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 2002; 20:1922-1925.
12. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001; 75:8340-8347.
13. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6:200-206.
14. Conley AJ, Kessler JA II, Boots LJ, McKenna PM, Schleif WA, Emini EA, et al. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J Virol 1996; 70:6751-6758.
15. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF 3rd, Burton DR. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994; 68:4821-4828.
16. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266:1024-1027.
17. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996; 70:1100-1108.
18. Pantophlet R, Burton DR. Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies. Trends Mol Med 2003; 9:468-473.
19. Scanlan CN, Pantophlet R, Wormald MR, Saphire EO, Calarese DA, Stanfield R, et al. The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12. In: Glycobiology and medicine. Edited by Axford JS. New York: Kluwer Academic/Plenum Publishers; 2003. pp. 205-218.
20. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 2004; 4:199-210.
21. Grundner C, Pancera M, Kang JM, Koch M, Sodroski J, Wyatt R. Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins. Virology 2004; 330:233-248.
22. Yang X, Wyatt R, Sodroski J. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol 2001; 75:1165-1171.
23. Spearman P. HIV vaccine development: lessons from the past and promise for the future. Curr HIV Res 2003; 1:101-120.
24. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993; 67:6642-6647.
25. Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, Purtscher M, et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 1994; 10:359-369.
26. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001; 75:10892-10905.
27. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001; 17:1757-1765.
28. Xu JY, Gorny MK, Palker T, Karwowska S, Zolla-Pazner S. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol 1991; 65:4832-4838.
29. Binley JM, Ditzel HJ, Barbas CF 3rd, Sullivan N, Sodroski J, Parren PW, et al. Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. AIDS Res Hum Retroviruses 1996; 12:911-924.
30. Earl PL, Broder CC, Doms RW, Moss B. Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J Virol 1997; 71:2674-2684.
31. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998; 280:1884-1888.
32. Sattentau QJ, Zolla-Pazner S, Poignard P. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 1995; 206:713-717.
33. Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001; 70:777-810.
34. Poignard P, Sabbe R, Picchio GR, Wang M, Gulizia RJ, Katinger H, et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 1999; 10:431-438.
35. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6:207-210.
36. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73:4009-4018.
37. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing anti-bodies. Nat Med 2005; 11:615-622.
38. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004; 78:13232-13252.
39. Mehandru S, Wrin T, Galovich J, Stiegler G, Vcelar B, Hurley A, et al. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J Virol 2004; 78:14039-14042.
40. Rusert P, Kuster H, Joos B, Misselwitz B, Gujer C, Leemann C, et al. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J Virol 2005; 79:8454-8469.
41. Parren PW, Mondor I, Naniche D, Ditzel HJ, Klasse PJ, Burton DR, et al. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J Virol 1998; 72:3512-3519.
42. Sattentau QJ, Moore JP. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med 1995; 182:185-196.
43. Moore JP, Cao Y, Qing L, Sattentau QJ, Pyati J, Koduri R, et al. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995; 69:101-109.
44. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998; 393:705-711.
45. Ren X, Sodroski J, Yang X. An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins. J Virol 2005; 79:5616-5624.
46. Barbato G, Bianchi E, Ingallinella P, Hurni WH, Miller MD, Ciliberto G, et al. Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. J Mol Biol 2003; 330:1101-1115.
47. Yang X, Kurteva S, Lee S, Sodroski J. Stoichiometry of antibody neutralization of human immunodeficiency virus type 1. J Virol 2005; 79:3500-3508.
48. Melikyan GB, Markosyan RM, Hemmati H, Delmedico MK, Lambert DM, Cohen FS. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 2000; 151:413-423.
49. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994; 91:9770-9774.
50. Bewley CA, Louis JM, Ghirlando R, Clore GM. Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J Biol Chem 2002; 277:14238-14245.
51. Root MJ, Kay MS, Kim PS. Protein design of an HIV-1 entry inhibitor. Science 2001; 291:884-888.
52. Eckert DM, Kim PS. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc Natl Acad Sci USA 2001; 98:11187-11192.
53. Binley JM, Cayanan CS, Wiley C, Schulke N, Olson WC, Burton DR. Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol 2003; 77:5678-5684.
54. Gorny MK, Zolla-Pazner S. Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41. J Virol 2000; 74:6186-6192.
55. de Rosny E, Vassell R, Jiang S, Kunert R, Weiss CD. Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J Virol 2004; 78:2627-2631.
56. Finnegan CM, Berg W, Lewis GK, DeVico AL. Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion. J Virol 2001; 75:11096-11105.
57. Follis KE, Larson SJ, Lu M, Nunberg JH. Genetic evidence that inter helical packing interactions in the gp41 core are critical for transition of the human immunodeficiency virus type 1 envelope glycoprotein to the fusion-active state. J Virol 2002; 76:7356-7362.
58. Zwick MB, Jensen R, Church S, Wang M, Stiegler G, Kunert R, et al. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 2005; 79:1252-1261.
59. Reeves JD, Lee FH, Miamidian JL, Jabara CB, Juntilla MM, Doms RW. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol 2005; 79:4991-4999.
60. Zwick MB, Komori HK, Stanfield RL, Church S, Wang M, Parren PW, et al. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol 2004; 78:3155-3161.
61. Ofek G, Tang M, Sambor A, Katinger H, Mascola JR, Wyatt R, et al. Structure and mechanistic analysis of the anti-HIV-1 antibody 2F5 in complex with its epitope. J Virol 2004; 78:10724-10737.
62. Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, Franti M, et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003; 77:10557-10565.
63. Kunert R, Wolbank S, Stiegler G, Weik R, Katinger H. Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Res Hum Retroviruses 2004; 20:755-762.
64. Schibli DJ, Montelaro RC, Vogel HJ. The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well-defined helix in dodecylphosphocholine micelles. Biochemistry 2001; 40:9570-9578.
65. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89:263-273.
66. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997; 387:426-430.
67. Tan K, Liu J, Wang J, Shen S, Lu M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci USA 1997; 94:12303-12308.
68. Bechinger B. Understanding peptide interactions with the lipid bilayer: a guide to membrane protein engineering. Curr Opin Chem Biol 2000; 4:639-644.
69. Pai EF, Klein MH, Chong P, Pedyczak A. Fab′-epitope complex from the HIV-1 cross-neutralizing monoclonal antibody 2F5. World Intellectual Property Organization. Patent WO-00/61618, 2000.
70. Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, Katinger H, et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005; 22:163-173.
71. Biron Z, Khare S, Samson AO, Hayek Y, Naider F, Anglister J. A monomeric 3(10)-helix is formed in water by a 13-residue peptide representing the neutralizing determinant of HIV-1 on gp41. Biochemistry 2002; 41:12687-12696.
72. Joyce JG, Hurni WM, Bogusky MJ, Garsky M, Liang X, Citron MP, et al. Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design. J Biol Chem 2002; 277:45811-45820.
73. McGaughey GB, Citron M, Danzeisen RC, Freidinger RM, Garsky VM, Hurni WM, et al. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. Biochemistry 2003; 42:3214-3223.
74. Menendez A, Chow KC, Pan OC, Scott JK. Human immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitope. J Mol Biol 2004; 338:311-327.
75. Schlehuber LD, Rose JK. Prediction and identification of a permissive epitope insertion site in the vesicular stomatitis virus glycoprotein. J Virol 2004; 78:5079-5087.
76. Poignard P, Moulard M, Golez E, Wang M, Gulizia RJ, Katinger H, et al. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J Virol 2003; 77:353-365.
77. Nyambi PN, Mbah HA, Burda S, Williams C, Gorny MK, Nadas A, et al. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J Virol 2000; 74:7096-7107.
78. Burrer R, Haessig-Einius S, Aubertin AM, Moog C. Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41. Virology 2005; 333:102-113.
79. Salzwedel K, West JT, Hunter E. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J Virol 1999; 73:2469-2480.
80. Munoz-Barroso I, Salzwedel K, Hunter E, Blumenthal R. Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J Virol 1999; 73:6089-6092.
81. Dimitrov AS, Rawat SS, Jiang S, Blumenthal R. Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion. Biochemistry 2003; 42:14150-14158.
82. Suarez T, Gallaher WR, Agirre A, Goni FM, Nieva JL. Membrane interface-interacting sequences within the ectodomain of the human immunodeficiency virus type 1 envelope glycoprotein: putative role during viral fusion. J Virol 2000; 74:8038-8047.
83. Grundner C, Mirzabekov T, Sodroski J, Wyatt R. Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins. J Virol 2002; 76:3511-3521.
84. Lay CS, Wilson KA, Kobe B, Kemp BE, Drummer HE, Poumbourios P. Expression and biochemical analysis of the entire HIV-2 gp41 ectodomain: determinants of stability map to N- and C-terminal sequences outside the 6-helix bundle core. FEBS Lett 2004; 567:183-188.
85. Cao J, Bergeron L, Helseth E, Thali M, Repke H, Sodroski J. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J Virol 1993; 67:2747-2755.
86. Hunter E. Mutational analyses of HIV-1 gp41 define a minimal membrane-anchor and a topological model for it and the tryptophan-rich membrane proximal domain. Fourth Frederick Workshop on the Cell Biology of Viral Entry. Frederick, Maryland, May 2004.
87. Giannecchini S, Bonci F, Pistello M, Matteucci D, Sichi O, Rovero P, et al. The membrane-proximal tryptophan-rich region in the transmembrane glycoprotein ectodomain of feline immunodeficiency virus is important for cell entry. Virology 2004; 320:156-166.
88. Sainz B Jr, Rausch JM, Gallaher WR, Garry RF, Wimley WC. The aromatic domain of the coronavirus class I viral fusion protein induces membrane permeabilization: putative role during viral entry. Biochemistry 2005; 44:947-958.
89. Garg H, Fuller FJ, Tompkins WA. Mechanism of feline immunodeficiency virus envelope glycoprotein-mediated fusion. Virology 2004; 321:274-286.
90. Freer G, Giannecchini S, Tissot A, Bachmann MF, Rovero P, Serres PF, et al. Dissection of seroreactivity against the tryptophan-rich motif of the feline immunodeficiency virus transmembrane glycoprotein. Virology 2004; 322:360-369.
91. Tong S, Yi F, Martin A, Yao Q, Li M, Compans RW. Three membrane-proximal amino acids in the human parainfluenza type 2 (HPIV 2) F protein are critical for fusogenic activity. Virology 2001; 280:52-61.
92. Zhou J, Dutch RE, Lamb RA. Proper spacing between heptad repeat B and the transmembrane domain boundary of the paramyxovirus SV5 F protein is critical for biological activity. Virology 1997; 239:327-339.
93. Baker KA, Dutch RE, Lamb RA, Jardetzky TS. Structural basis for paramyxovirus-mediated membrane fusion. Mol Cell 1999; 3:309-319.
94. McNew JA, Weber T, Engelman DM, Sollner TH, Rothman JE. The length of the flexible SNAREpin juxtamembrane region is a critical determinant of SNARE-dependent fusion. Mol Cell 1999; 4:415-421.
95. Jeetendra E, Ghosh K, Odell D, Li J, Ghosh HP, Whitt MA. The membrane-proximal region of vesicular stomatitis virus glycoprotein G ectodomain is critical for fusion and virus infectivity. J Virol 2003; 77:12807-12818.
96. Killian JA, von Heijne G. How proteins adapt to a membrane-water interface. Trends Biochem Sci 2000; 25:429-434.
97. White SH, Ladokhin AS, Jayasinghe S, Hristova K. How membranes shape protein structure. J Biol Chem 2001; 276:32395-32398.
98. Schibli DJ, Epand RF, Vogel HJ, Erjand RM. Tryptophan-rich antimicrobial peptides: comparative properties and membrane interactions. Biochem Cell Biol 2002; 80:667-677.
99. Saez-Cirion A, Nir S, Lorizate M, Agirre A, Cruz A, Perez-Gil J, et al. Sphingomyelin and cholesterol promote HIV-1 gp41 pretransmembrane sequence surface aggregation and membrane restructuring. J Biol Chem 2002; 277:21776-21785.
100. Alfsen A, Bomsel M. HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide. J Biol Chem 2002; 277:25649-25659.
101. Vincent N, Genin C, Malvoisin E. Identification of a conserved domain of the HIV-1 transmembrane protein gp41 which interacts with cholesteryl groups. Biochim Biophys Acta 2002; 1567:157-164.
102. Epand RF, Sayer BG, Epand RM. The tryptophan-rich region of HIV gp41 and the promotion of cholesterol-rich domains. Biochemistry 2005; 44:5525-5531.
103. Epand RM, Sayer BG, Epand RF. Peptide-induced formation of cholesterol-rich domains. Biochemistry 2003; 42:14677-14689.
104. Kweon DH, Kim CS, Shin YK. Regulation of neuronal SNARE assembly by the membrane. Nat Struct Biol 2003; 10:440-447.
105. Kweon DH, Kim CS, Shin YK. Insertion of the membrane-proximal region of the neuronal SNARE coiled coil into the membrane. J Biol Chem 2003; 278:12367-12373.
106. Eckhart L, Raffelsberger W, Ferko B, Klima A, Purtscher M, Katinger H, et al. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. J Gen Virol 1996; 77 (Pt 9):2001-2008.
107. Muster T, Guinea R, Trkola A, Purtscher M, Klima A, Steindl F, et al. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 1994; 68:4031-4034.
108. Coeffier E, Clement JM, Cussac V, Khodaei-Boorane N, Jehanno M, Rojas M, et al. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine 2000; 19:684-693.
109. Liang X, Munshi S, Shendure J, Mark 3rd G, Davies ME, Freed DC, et al. Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. Vaccine 1999; 17:2862-2872.
110. Chakrabarti BK, Ling X, Yang ZY, Montefiori DC, Panel A, Kong WP, et al. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. Vaccine 2005; 23:3434-3445.
111. Marusic C, Rizza P, Lattanzi L, Mancini C, Spada M, Belardelli F, et al. Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. J Virol 2001; 75:8434-8439.
112. Ho J, Uger RA, Zwick MB, Luscher MA, Barber BH, MacDonald KS. Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response. Vaccine 2005; 23:1559-1573.
113. Zhang H, Huang Y, Fayad R, Spear GT, Qiao L. Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles. J Virol 2004; 78:8342-8348.
114. Arnold GF, Velasco PK, Wrin T, Ma X, Geisler S, Tian Y, et al. Neutralization of diverse HIV-1 primary isolates elicited by gp41 ELDKWA-displaying human rhinoviruses selected form combinatorial libraries. AIDS Vaccine 2004 International Conference. Lausanne, Switzerland.
115. Opalka D, Pessi A, Bianchi E, Ciliberto G, Schleif W, McElhaugh M, et al. Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay. J Immunol Methods 2004; 287:49-65.
116. Calarota S, Jansson M, Levi M, Broliden K, Libonatti O, Wigzell H, et al. Immunodominant glycoprotein 41 epitope identified by seroreactivity in HIV type 1-infected individuals. AIDS Res Hum Retroviruses 1996; 12:705-713.
117. Horal P, Svennerholm B, Jeansson S, Rymo L, Hall WW, Vahlne A. Continuous epitopes of the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein and reactivity of human sera to synthetic peptides representing various HIV-1 isolates. J Virol 1991; 65:2718-2723.
118. Ugen KE, Srikantan V, Goedert JJ, Nelson RP Jr, Williams WV, Weiner DB. Vertical transmission of human immunodeficiency virus type 1: seroreactivity by maternal antibodies to the carboxy region of the gp41 envelope glycoprotein. J Infect Dis 1997; 175:63-69.
119. Broliden PA, von Gegerfelt A, Clapham P, Rosen J, Fenyo EM, Wahren B, et al. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci USA 1992; 89:461-465.
120. Kimura K, Arata Y, Yasuda T, Kinosita K, Nakanishi M. Location of membrane-bound hapten with different length spacers. Immunology 1990; 69:323-328.
121. Kimura K, Arata Y, Yasuda T, Kinosita K Jr, Nakanishi M. Fluorescence quenching measurements of the membrane bound lipid haptens with different length spacers. Biochim Biophys Acta 1992; 1104:9-14.
122. Vanlandschoot P, Beirnaert E, Barrere B, Calder L, Millar B, Wharton S, et al. An antibody which binds to the membrane-proximal end of influenza virus haemagglutinin (H3 subtype) inhibits the low-pH-induced conformational change and cell-cell fusion but does not neutralize virus. J Gen Virol 1998; 79 (Pt 7):1781-1791.
123. Lenz O, Dittmar MT, Wagner A, Ferko B, Vorauer-Uhl K, Stiegler G, et al. Trimeric membrane anchored gp41 inhibits HIV membrane fusion. J Biol Chem 2004; 280:4095-4101.
124. Jenski LJ, Nanda PK, Jiricko P, Stillwell W. Docosahexaenoic acid-containing phosphatidylcholine affects the binding of monoclonal antibodies to purified Kb reconstituted into liposomes. Biochim Biophys Acta 2000; 1467:293-306.
125. Gomez-Gutierrez J, Rodriguez-Crespo I, Peterson DL, Gavilanes F. Antigenicity of hepatitis B surface antigen proteins reconstituted with phospholipids. Biochim Biophys Acta 1995; 1233:205-212.
126. Haynes BF, Fleming J, St Clair WE, Katinger H, Stiegler G, Kunert R, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005; 308:1906-1908.
127. Grimaldi CM, Hicks R, Diamond B. B cell selection and susceptibility to autoimmunity. J Immunol 2005; 174:1775-1781.
128. Goodnow CC, Sprent J, de St Groth BF, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005; 435:590-597.
129. Ray SK, Putterman C, Diamond B. Pathogenic autoantibodies are routinely generated during the response to foreign antigen: a paradigm for autoimmune disease. Proc Natl Acad Sci USA 1996; 93:2019-2024.
130. Edwards BM, Barash SC, Main SH, Choi GH, Minter R, Ullrich S, et al. The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. J Mol Biol 2003; 334:103-118.
131. Zwick MB, Parren PW, Saphire EO, Church S, Wang M, Scott JK, et al. Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J Virol 2003; 77:5863-5876.
132. Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, et al. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci USA 2002; 99:6913-6918.
133. Bassing CH, Swat W, Alt FW. The mechanism and regulation of chromosomal V(D)J recombination. Cell 2002; 109 (supp):S45-S55.
134. Zhang Z, Burrows PD, Cooper MD. The molecular basis and biological significance of VH replacement. Immunol Rev 2004; 197:231-242.
135. Jankovic M, Casellas R, Yannoutsos N, Wardemann H, Nussenzweig MC. RAGs and regulation of autoantibodies. Annu Rev Immunol 2004; 22:485-501.
136. Ait-Azzouzene D, Skog P, Retter M, Kouskoff V, Hertz M, Lang J, et al. Tolerance-induced receptor selection: scope, sensitivity, locus specificity, and relationship to lymphocyte-positive selection. Immunol Rev 2004; 197:219-230; [Erratum in: 200: 272.]
137. Barbas CF 3rd, Collet TA, Amberg W, Roben P, Binley JM, Hoekstra D, et al. Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J Mol Biol 1993; 230:812-823.
138. Wu TT, Johnson G, Kabat EA. Length distribution of CDRH3 in antibodies. Proteins 1993; 16:1-7.
139. Snapper CM, Marcu KB, Zelazowski P. The immunoglobulin class switch: beyond "accessibility". Immunity 1997; 6:217-223.
140. Taylor CE. Cytokines as adjuvants for vaccines: antigen-specific responses differ from polyclonal responses. Infect Immun 1995; 63:3241-3244.
141. Ahlers JD, Belyakov IM, Berzofsky JA. Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines. Curr Mol Med 2003; 3:285-301.
142. Decroix N, Pamonsinlapatham P, Quan CP, Bouvet JP. Impairment by mucosal adjuvants and cross-reactivity with variant peptides of the mucosal immunity induced by injection of the fusion peptide PADRE-ELDKWA. Clin Diagn Lab Immunol 2003; 10:1103-1108.
143. Zinkernagel RM. Localization dose and time of antigens determine immune reactivity. Semin Immunol 2000; 12:163-171.
144. Burton DR, Parren PW. Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection? Nat Med 2000; 6:123-125.
145. Louis JM, Nesheiwat I, Chang L, Clore GM, Bewley CA. Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J Biol Chem 2003; 278:20278-20285.
146. Sanner MF. Python: a programming language for software integration and development. J Mol Graph Model 1999; 17:57-61.
147. Luo M, Yuan F, Liu Y, Jiang S, Song X, Jiang P, et al. Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment. Vaccine 2005; [Epub ahead of print].
148. Langhammer S, Fiebig U, Kurth R, Denner J. Neutralising antibodies against the transmembrane protein of feline leukaemia virus (FeLV). Vaccine 2005; 23:3341-3348.
149. Fiebig U, Stephan O, Kurth R, Denner J. Neutralizing antibodies against conserved domains of p15E of porcine endogenous retroviruses: basis for a vaccine for xenotransplantation? Virology 2003; 307:406-413.